为您找到相关结果约500个

你是不是要搜索 期刊1702PEfficacy+and+safety+of+apatinib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib:+An+open-label,+multicenter,+single-arm,+phase+II+trial 点击跳转

Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatiniband sunitinib: An open-label, multicenter, single-arm, phase II trial

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After TreatmentWith Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.

Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors AfterFailure of Imatinib and Sunitinib

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter,open-label, phase II trial

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label PhaseII Clinical Trial

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor afterimatinib

Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractoryto imatinib and sunitinib: A single arm, multicenters, phase 2 trial.

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors asa Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure ofimatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatiniband sunitinib treatment A meta-analysis

Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial

Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase2 trial

为您找到相关结果约500个

共500条页码: 1/34页15条/页